TY - JOUR
T1 - Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel
AU - Langer, C. J.
AU - Hirsh, V.
AU - Okamoto, I.
AU - Lin, F. J.
AU - Wan, Y.
AU - Whiting, S.
AU - Ong, T. J.
AU - Renschler, M. F.
AU - Botteman, M. F.
N1 - Funding Information:
This study was funded by Celgene Corporation. We thank John Carter for editorial assistance in the preparation of the manuscript.
Funding Information:
CJL received honorarium/consulting fee and has served as an advisor for Celgene Corporation. VH is a consultant for Celgene Corporation. F-JL, YW, and MFB are employees, and MFB is also a shareholderof Pharmerit International, an independent contract research organisation that received research funding from Celgene Corporation. SW, TJO, and MFR are employees of Celgene Corporation. The remaining authors declare no conflict of interest.
Publisher Copyright:
© 2015 Cancer Research UK. All rights reserved.
PY - 2015/6/30
Y1 - 2015/6/30
N2 - This analysis compared the quality-adjusted survival and clinical outcomes of albumin-bound paclitaxel+carboplatin (nab-PC) vs solvent-based paclitaxel+carboplatin (sb-PC) as first-line therapy in advanced non-small-cell lung cancer (NSCLC) in older patients.Methods:Using age-based subgroup data from a randomised Phase-3 clinical trial, nab-PC and sb-PC were compared with respect to overall response rate (ORR), overall survival (OS), progression-free survival (PFS), quality of life (QoL), safety/toxicity, and quality-adjusted time without symptoms or toxicity (Q-TWiST) with ages ≥60 and ≥70 years as cut points.Results:Among patients aged ≥60 years (N=546), nab-PC (N=265) significantly increased ORR and prolonged OS, despite a non-significant improvement in PFS, vs sb-PC (N=281). Nab-PC improved QoL and was associated with less neuropathy, arthralgia, and myalgia but resulted in more anaemia and thrombocytopenia. Nab-PC yielded significant Q-TWiST benefits (11.1 vs 9.8 months; 95% CI of gain: 0.2-2.6), with a relative Q-TWiST gain of 10.8% (ranging from 6.4% to 15.1% in threshold analysis). In the ≥70 years age group, nab-PC showed similar, but non-significant, ORR, PFS, and Q-TWiST benefits and significantly improved OS and QoL.Conclusion:Nab-PC as first-line therapy in older patients with advanced NSCLC increased ORR, OS, and QoL and resulted in quality-adjusted survival gains compared with standard sb-PC.
AB - This analysis compared the quality-adjusted survival and clinical outcomes of albumin-bound paclitaxel+carboplatin (nab-PC) vs solvent-based paclitaxel+carboplatin (sb-PC) as first-line therapy in advanced non-small-cell lung cancer (NSCLC) in older patients.Methods:Using age-based subgroup data from a randomised Phase-3 clinical trial, nab-PC and sb-PC were compared with respect to overall response rate (ORR), overall survival (OS), progression-free survival (PFS), quality of life (QoL), safety/toxicity, and quality-adjusted time without symptoms or toxicity (Q-TWiST) with ages ≥60 and ≥70 years as cut points.Results:Among patients aged ≥60 years (N=546), nab-PC (N=265) significantly increased ORR and prolonged OS, despite a non-significant improvement in PFS, vs sb-PC (N=281). Nab-PC improved QoL and was associated with less neuropathy, arthralgia, and myalgia but resulted in more anaemia and thrombocytopenia. Nab-PC yielded significant Q-TWiST benefits (11.1 vs 9.8 months; 95% CI of gain: 0.2-2.6), with a relative Q-TWiST gain of 10.8% (ranging from 6.4% to 15.1% in threshold analysis). In the ≥70 years age group, nab-PC showed similar, but non-significant, ORR, PFS, and Q-TWiST benefits and significantly improved OS and QoL.Conclusion:Nab-PC as first-line therapy in older patients with advanced NSCLC increased ORR, OS, and QoL and resulted in quality-adjusted survival gains compared with standard sb-PC.
UR - http://www.scopus.com/inward/record.url?scp=84934439813&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84934439813&partnerID=8YFLogxK
U2 - 10.1038/bjc.2015.181
DO - 10.1038/bjc.2015.181
M3 - Article
C2 - 26035702
AN - SCOPUS:84934439813
VL - 113
SP - 20
EP - 29
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 1
ER -